Innate Pharma Archives

News and Trends 6 Dec 2016

How is European Immuno-Oncology fighting Blood Cancer?

From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field. The 58th ASH annual meeting is wrapping up today, after the best companies […]

December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

aacr 2016 merus transgene debiopharma innate

News and Trends 21 Apr 2016

These EU Biotechs presented groundbreaking results at World Biggest Cancer Meeting

The annual meeting of the American Association for Cancer Research (AACR) has just finished. From Europe, who made a splash with their results? The AACR annual meeting is the world’s biggest conference in Cancer research, and the must-attend event for Biotechs developing cancer therapies. The 2016 edition took place in New Orleans (US) from the […]

April 21, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 7 Jan 2016

3 French Bioentrepreneurs are Awarded for Being Stubborn

Building a company is extremely difficult and obstination is sometimes needed to reach success. The organisation, France Biotech, has given a price to the founder of Innate-Pharma, OSE Pharma and Effimune for their respective success. Why? From left to right, Hervé Brailly, CEO & Founder of Innate-Pharma, Denis Lucquin, Managing Director of Sofinnova Partners, Maryvonne Hiance, […]

January 7, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a […]

November 24, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 28 May 2015

Biotechs outperformed in the top 40 European Tech Companies

EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs (Small and Medium-size companies), announced the launch of Tech 40, a label recognizing innovative European SMEs. Tech 40 puts young tech companies listed on Euronext markets – in Amsterdam, Brussels, Lisbon or Paris – under the spotlight. Companies awarded with the Tech 40 are operating in […]

May 28, 2015 - 2 minutesmins - By Nicolas Sainte-Foie

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us